CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenues:
Total revenue	$ 31,249	$ 29,752	$ 6,761
Costs and expenses:
Cost of revenue	3,423	4,023	4,713
Research and development	98,384	77,813	43,813
General and administrative	32,412	25,133	23,619
Licensing	14,658	7,937
Revaluation of contingent consideration	(26,900)	4,700	24,339
Intangible asset impairment	6,629
Total costs and expenses	128,606	119,606	96,484
Loss from operations	(97,357)	(89,854)	(89,723)
Other income (expense), net	8,509	2,946	(1,142)
Loss before income taxes	(88,848)	(86,908)	(90,865)
Income tax benefit	(367)
Net loss	$ (88,481)	$ (86,908)	$ (90,865)
Net loss per share, basic	$ (1.27)	$ (1.33)	$ (1.60)
Net loss per share, diluted	$ (1.27)	$ (1.33)	$ (1.60)
Weighted average common shares outstanding, basic	69,808,855	65,213,944	56,730,583
Weighted average common shares outstanding, diluted	69,808,855	65,213,944	56,730,583
Other comprehensive loss:
Unrealized gain (loss) on marketable securities, net of tax of $0	$ 791	$ (673)	$ (229)
Foreign currency translation adjustment			99
Total other comprehensive gain (loss)	791	(673)	(130)
Comprehensive loss	(87,690)	(87,581)	(90,995)
Contract research
Revenues:
Total revenue	3,035	4,395	5,830
Licensing
Revenues:
Total revenue	$ 28,214	25,100	809
Other
Revenues:
Total revenue		$ 257	$ 122